1131 related articles for article (PubMed ID: 17118987)
1. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.
Murthy AK; Chambers JP; Meier PA; Zhong G; Arulanandam BP
Infect Immun; 2007 Feb; 75(2):666-76. PubMed ID: 17118987
[TBL] [Abstract][Full Text] [Related]
2. Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach.
Li W; Guentzel MN; Seshu J; Zhong G; Murthy AK; Arulanandam BP
Clin Vaccine Immunol; 2007 Dec; 14(12):1537-44. PubMed ID: 17942608
[TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection.
Cong Y; Jupelli M; Guentzel MN; Zhong G; Murthy AK; Arulanandam BP
Vaccine; 2007 May; 25(19):3773-80. PubMed ID: 17349723
[TBL] [Abstract][Full Text] [Related]
4. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele.
Murthy AK; Cong Y; Murphey C; Guentzel MN; Forsthuber TG; Zhong G; Arulanandam BP
Infect Immun; 2006 Dec; 74(12):6722-9. PubMed ID: 17015458
[TBL] [Abstract][Full Text] [Related]
5. Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice.
Li W; Gudipaty P; Li C; Henderson KK; Ramsey KH; Murthy AK
Immunol Cell Biol; 2019 Jan; 97(1):85-91. PubMed ID: 30051926
[TBL] [Abstract][Full Text] [Related]
6. Immunization with chlamydial plasmid protein pORF5 DNA vaccine induces protective immunity against genital chlamydial infection in mice.
Li Z; Wang S; Wu Y; Zhong G; Chen D
Sci China C Life Sci; 2008 Nov; 51(11):973-80. PubMed ID: 18989639
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.
Li W; Murthy AK; Guentzel MN; Chambers JP; Forsthuber TG; Seshu J; Zhong G; Arulanandam BP
Infect Immun; 2010 Sep; 78(9):3942-9. PubMed ID: 20605976
[TBL] [Abstract][Full Text] [Related]
8. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
[TBL] [Abstract][Full Text] [Related]
9. Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection.
Li W; Murthy AK; Guentzel MN; Seshu J; Forsthuber TG; Zhong G; Arulanandam BP
J Immunol; 2008 Mar; 180(5):3375-82. PubMed ID: 18292563
[TBL] [Abstract][Full Text] [Related]
10. A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge.
Murthy AK; Chaganty BK; Li W; Guentzel MN; Chambers JP; Seshu J; Zhong G; Arulanandam BP
FEMS Immunol Med Microbiol; 2009 Mar; 55(2):271-9. PubMed ID: 19281569
[TBL] [Abstract][Full Text] [Related]
11. Intranasal vaccination with Chlamydia pneumoniae induces cross-species immunity against genital Chlamydia muridarum challenge in mice.
Manam S; Chaganty BK; Evani SJ; Zafiratos MT; Ramasubramanian AK; Arulanandam BP; Murthy AK
PLoS One; 2013; 8(5):e64917. PubMed ID: 23741420
[TBL] [Abstract][Full Text] [Related]
12. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.
Chaganty BK; Murthy AK; Evani SJ; Li W; Guentzel MN; Chambers JP; Zhong G; Arulanandam BP
Vaccine; 2010 Mar; 28(11):2323-9. PubMed ID: 20056182
[TBL] [Abstract][Full Text] [Related]
13. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
Hickey DK; Aldwell FE; Beagley KW
Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
[TBL] [Abstract][Full Text] [Related]
14. Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection.
Hickey DK; Aldwell FE; Beagley KW
Vaccine; 2010 Feb; 28(7):1668-72. PubMed ID: 20026449
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with the polymorphic membrane protein A reduces Chlamydia muridarum induced genital tract pathology.
Müller T; Becker E; Stallmann S; Waldhuber A; Römmler-Dreher F; Albrecht S; Mohr F; Hegemann JH; Miethke T
Vaccine; 2017 May; 35(21):2801-2810. PubMed ID: 28413133
[TBL] [Abstract][Full Text] [Related]
16. A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.
Li W; Murthy AK; Lanka GK; Chetty SL; Yu JJ; Chambers JP; Zhong G; Forsthuber TG; Guentzel MN; Arulanandam BP
Vaccine; 2013 Nov; 31(48):5722-8. PubMed ID: 24096029
[TBL] [Abstract][Full Text] [Related]
17. The duration of Chlamydia muridarum genital tract infection and associated chronic pathological changes are reduced in IL-17 knockout mice but protection is not increased further by immunization.
Andrew DW; Cochrane M; Schripsema JH; Ramsey KH; Dando SJ; O'Meara CP; Timms P; Beagley KW
PLoS One; 2013; 8(9):e76664. PubMed ID: 24073293
[TBL] [Abstract][Full Text] [Related]
18. Expression library immunization confers partial protection against Chlamydia muridarum genital infection.
McNeilly CL; Beagley KW; Moore RJ; Haring V; Timms P; Hafner LM
Vaccine; 2007 Mar; 25(14):2643-55. PubMed ID: 17239501
[TBL] [Abstract][Full Text] [Related]
19. The
Verma R; Sahu R; Dixit S; Duncan SA; Giambartolomei GH; Singh SR; Dennis VA
Front Immunol; 2018; 9():2369. PubMed ID: 30374357
[TBL] [Abstract][Full Text] [Related]
20. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
Yu H; Jiang X; Shen C; Karunakaran KP; Jiang J; Rosin NL; Brunham RC
Infect Immun; 2010 May; 78(5):2272-82. PubMed ID: 20231405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
